CasInvent Pharma
Oncology Therapeutics
Overview
CasInvent Pharma | CasInvent Pharma. Fighting resistant tumors with best-in-class inhibitors of casein kinase 1 (CK1).
Funding and backers
Backers
1
i&i Bio
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
2020
Founded
Backed byfrom the funds' portfolios and accelerator catalogs
Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
ETX-19477 is a selective PARG inhibitor designed to address DNA damage response vulnerabilities and expand precision treatment options for…
TwoStep Therapeutics. Developing tumor-targeted therapies with broad applicability across solid tumors.
BetaGlue Therapeutics — YntraDose®: a one-time, image-guided Yttrium-90 injection designed for durable local tumor control alongside…
Alterome is a clinical-stage precision oncology company developing first-in-class, alteration-specific therapies for AKT E17K- and…
PanTher Therapeutics. PanTher’s technology unleashes the inherent power of cancer-fighting drugs by enabling continuous, high-dose…
IDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells…
Connections
List
Graph
Found in company registers, site code, DNS and hiring. Each connection shows how sure we are and the evidence, with its source and date.
Shared investors
i&i BioVia a fund
Click a company to open it. Dashed lines are likely connections. The second step of the network is part of the Pro plan.
Owner
Same company
Same group
Likely